Telehealth company Hims & Hers Health (NYSE: HIMS) met Wall Street’s revenue expectations in Q3 2026, with sales up 48.6% year on year to $890.4 million. On the other hand, next quarter’s revenue guidance of $885 million was less impressive, coming in 7.1% below analysts’ estimates. Its non-GAAP profit of $0.03 per share was 82% below analysts’ consensus estimates.

Is now the time to buy HIMS? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Hims & Hers Health’s third quarter results prompted a negative market reaction, as the company’s GAAP loss was notably below Wall Street expectations despite revenue growth aligning closely with analyst forecasts. Leadership attributed the quarter’s outcome to measured marketing in its U.S. weight loss specialty and subscriber transitions related to international brand consolidation. CEO Andrew Dudum acknowledged the impact of intentionally reduced marketing, stating, “Each of these choices trades near-term subscriber growth for a stronger position in the years that follow.”

Looking ahead, management’s guidance reflects a focus on expanding product assortment, integrating new pharmaceutical partnerships, and scaling international operations. Executives emphasized that upcoming investments in AI-driven care, marketing, and specialty launches—particularly in metabolic health and peptides—are expected to drive long-term growth, even if they create near-term volatility. CFO Yemi Okupe cautioned that, “Investments that we make to fulfill this objective are likely to result in some quarter-to-quarter variability, but position us well over the long term.”

Key insights from management’s remarks

Management attributed the quarter’s performance to deliberate marketing pullbacks in the U.S. and ongoing integration of new specialties and infrastructure investments, especially in AI and international expansion.

• Intentional marketing pullback: The company reduced domestic marketing spend in its weight loss specialty to prepare for a broader product assortment and stronger customer experience ahead of the new year. This decision was aimed at establishing a more sustainable foundation for long-term growth rather than maximizing near-term subscriber additions.
• Strategic product partnerships: Hims & Hers expanded its collaboration with major pharmaceutical companies, notably Novo and Lilly, to offer a wider range of branded weight loss medications. Management expects this broader selection to improve customer acquisition and retention as the metabolic health segment matures.
• International brand consolidation: The company began consolidating its portfolio under the unified Hims & Hers brands across key international markets such as the U.K., Germany, and Australia. This transition, supported by the Eucalyptus acquisition, resulted in some short-term subscriber volatility but is expected to enhance global brand recognition and operational efficiency.
• AI-native care experience rollout: Hims & Hers accelerated the deployment of its proprietary AI platform, which now supports a majority of weight loss customers and is set to expand into other specialties. CTO Mo Elshenawy highlighted that customers with access to the AI-native experience are interacting with care teams more frequently, improving engagement and adherence.
• Expansion into complex care categories: The company launched new offerings in testosterone replacement therapy and is preparing to introduce its Peptides+ category. These efforts leverage in-house pharmacy and lab infrastructure, enabling Hims & Hers to provide more comprehensive and controlled specialty care.

Drivers of future performance

Management expects near-term performance to be shaped by expanded product offerings, increased international investment, and continued adoption of AI-driven care—while cautioning that these moves may pressure margins and subscriber trends.

• Broader product assortment and partnerships: Upcoming launches of Lilly’s Zepbound and Foundayo, expansion with Novo’s pipeline, and the introduction of multi-month subscription models are expected to drive customer acquisition and retention, especially in the weight loss category. Management believes assortment breadth will be critical in attracting and retaining diverse customer segments.
• Aggressive international investment: The company plans to intensify marketing and pricing actions in the U.K. and Germany, aiming to capture share in markets where digital health adoption is accelerating. Leadership anticipates that while these moves may create short-term volatility, they will position the company for stronger revenue and profitability as international markets mature.
• Operational leverage through AI and technology: Hims & Hers is investing heavily in engineering and AI talent, with expectations that these investments will yield improved operating efficiencies, higher retention, and cost leverage over time. However, management acknowledges the risk of elevated expenses as the company scales both technology and core infrastructure.

Catalysts in upcoming quarters

Looking ahead, the StockStory team will be watching (1) whether expanded product assortments in metabolic health and testosterone drive a recovery in subscriber growth, (2) how the company executes its intensified marketing and pricing strategy in the U.K. and Germany, and (3) the pace of adoption and engagement with the AI-native care platform. We will also monitor the rollout and regulatory progress of new peptide therapies as a potential driver of longer-term revenue diversification.

Hims & Hers Health currently trades at $22.16, down from $23.04 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).

High quality stocks for all market conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.